Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)

Bibliographic details

Authors

S. Gampenrieder, V. Dezentje, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, C. Serrano, D. Costa, E. Blondeaux, L. Del Mastro, F. Bertucci, A. Goncalves, R. Bartsch, A. Deleuze, A. Salgado, M. Vitorino, C. Tinchon, Ladislav Pecen, G. Rinnerthaler, R. Greil

Publication year

2022

Publication type

Abstrakt

Periodical

Annals of Oncology

Bibliographic citation

GAMPENRIEDER, S., DEZENTJE, V., LAMBERTINI, M., DE NONNEVILLE, A., MARHOLD, M., LE DU, F., SERRANO, C., COSTA, D., BLONDEAUX, E., DEL MASTRO, L., BERTUCCI, F., GONCALVES, A., BARTSCH, R., DELEUZE, A., SALGADO, A., VITORINO, M., TINCHON, C., PECEN, Ladislav, RINNERTHALER, G., GREIL, R. Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT). Annals of Oncology. 2022, 33(Suppl. 3), S208-S208. ISSN 0923-7534. E-ISSN 1569-8041
Dostupné z: doi:10.1016/j.annonc.2022.03.196

DOI

10.1016/j.annonc.2022.03.196

ID

557826